Stelios Papadopoulos's most recent trade in Exelixis Inc was a trade of 9,812 Common Stock done . Disclosure was reported to the exchange on May 29, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Exelixis Inc | Stelios Papadopoulos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 9,812 | 1,289,228 (0%) | 0% | 0 | Common Stock | |
| Exelixis Inc | Stelios Papadopoulos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2025 | 20,634 | 0 | - | - | Option (right to buy) | |
| Exelixis Inc | Stelios Papadopoulos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.77 per share. | 15 May 2025 | 20,634 | 1,300,050 (0%) | 0% | 19.8 | 407,934 | Common Stock |
| Exelixis Inc | Stelios Papadopoulos | Director | Sale of securities on an exchange or to another person at price $ 44.35 per share. | 15 May 2025 | 20,634 | 1,279,416 (0%) | 0% | 44.4 | 915,118 | Common Stock |
| Exelixis Inc | Stelios Papadopoulos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2025 | 15,874 | 0 | - | - | Option (right to buy) | |
| Exelixis Inc | Stelios Papadopoulos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.50 per share. | 15 May 2025 | 15,874 | 1,295,290 (0%) | 0% | 20.5 | 325,417 | Common Stock |
| Exelixis Inc | Stelios Papadopoulos | Director | Sale of securities on an exchange or to another person at price $ 44.35 per share. | 15 May 2025 | 15,874 | 1,279,416 (0%) | 0% | 44.4 | 704,012 | Common Stock |
| Regulus Therapeutics Inc | Stelios Papadopoulos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2025 | 62,500 | 1,040,888 (4%) | 0% | 0 | Common Stock | |
| Ovid Therapeutics Inc | Stelios Papadopoulos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 90,000 | 90,000 | - | - | Stock Option (right to buy) | |
| Exelixis Inc | Stelios Papadopoulos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 18,838 | 1,279,416 (0%) | 0% | 0 | Common Stock | |
| Regulus Therapeutics Inc | Stelios Papadopoulos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2024 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Exelixis Inc | Stelios Papadopoulos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.57 per share. | 20 May 2024 | 11,686 | 1,272,015 (0%) | 0% | 19.6 | 228,695 | Common Stock |
| Exelixis Inc | Stelios Papadopoulos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2024 | 11,686 | 0 | - | - | Option (right to buy) | |
| Exelixis Inc | Stelios Papadopoulos | Director | Sale of securities on an exchange or to another person at price $ 21.00 per share. | 20 May 2024 | 11,437 | 1,260,578 (0%) | 0% | 21 | 240,177 | Common Stock |
| Regulus Therapeutics Inc | Stelios Papadopoulos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Stelios Papadopoulos | Director | Grant, award, or other acquisition of securities at price $ 1.60 per share. | 14 Mar 2024 | 250,000 | 978,388 (4%) | 1% | 1.6 | 400,000 | Common Stock |
| Regulus Therapeutics Inc | Stelios Papadopoulos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2023 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Stelios Papadopoulos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Regulus Therapeutics Inc | Stelios Papadopoulos | Director | Grant, award, or other acquisition of securities at price $ 0.90 per share. | 13 Apr 2023 | 222,198 | 728,388 (3%) | 1% | 0.9 | 200,000 | Common Stock |
| Biogen Inc | Stelios Papadopoulos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 2,255 | 10,095 (0%) | 0% | 0 | Common Stock | |
| Regulus Therapeutics Inc | Stelios Papadopoulos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Exelixis Inc | Stelios Papadopoulos | Director | Sale of securities on an exchange or to another person at price $ 19.56 per share. | 22 Feb 2022 | 84,515 | 1,220,036 (0%) | 0% | 19.6 | 1,653,113 | Common Stock |
| Regulus Therapeutics Inc | Stelios Papadopoulos | Director | Grant, award, or other acquisition of securities at price $ 0.36 per share. | 30 Nov 2021 | 2,222,222 | 5,061,929 (24%) | 10% | 0.4 | 800,000 | Common Stock |
| Biogen Inc | Stelios Papadopoulos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2021 | 1,275 | 7,840 (0%) | 0% | 0 | Common Stock | |
| Exelixis Inc | Stelios Papadopoulos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2021 | 40,000 | 0 | - | - | Option (right to buy) | |
| Exelixis Inc | Stelios Papadopoulos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.38 per share. | 11 May 2021 | 40,000 | 1,293,600 (0%) | 0% | 3.4 | 135,200 | Common Stock |
| Exelixis Inc | Stelios Papadopoulos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.13 per share. | 11 May 2021 | 40,000 | 1,258,675 (0%) | 0% | 3.1 | 125,200 | Common Stock |
| Exelixis Inc | Stelios Papadopoulos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.30 per share. | 11 May 2021 | 40,000 | 1,228,897 (0%) | 0% | 6.3 | 252,000 | Common Stock |
| Exelixis Inc | Stelios Papadopoulos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2021 | 40,000 | 0 | - | - | Option (right to buy) | |
| Exelixis Inc | Stelios Papadopoulos | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2021 | 40,000 | 0 | - | - | Option (right to buy) | |
| Exelixis Inc | Stelios Papadopoulos | Director | Sale of securities on an exchange or to another person at price $ 24.95 per share. | 11 May 2021 | 10,222 | 1,218,675 (0%) | 0% | 25.0 | 255,039 | Common Stock |
| Exelixis Inc | Stelios Papadopoulos | Director | Sale of securities on an exchange or to another person at price $ 25.01 per share. | 11 May 2021 | 5,473 | 1,288,127 (0%) | 0% | 25.0 | 136,880 | Common Stock |
| Exelixis Inc | Stelios Papadopoulos | Director | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 11 May 2021 | 5,075 | 1,253,600 (0%) | 0% | 25 | 126,875 | Common Stock |